NASDAQ:IMNM
Immunome Inc.
Immunome Inc.'s revenue fell 23.2% in fiscal 2025 to $6.9M while operating margin rose to −3228.8%. Free cash flow was −$200.6M, −2890.1% of revenue, and the diluted share count rose 49.0%.Summary generated from Immunome Inc.'s SEC filings. Latest annual report filed Mar 3, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$6.9M
Revenue growth−23.2%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−3228.8%
Net margin−3060.0%
ROICn/a
Return on equity−52.1%
Debt / equityn/a
Free cash flow−$200.6M
FCF margin−2890.1%
Share count change+49.0%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | 14 | 9 | 7 |
| Operating income | −25 | −37 | −110 | −306 | −224 |
| Net income | −25 | −37 | −107 | −293 | −212 |
| Free cash flow | −18 | −29 | −8 | −118 | −201 |
Recent filings
- 8-KEntry into a material agreement
Oct 5, 2026 - 4Insider transaction report
Sep 15, 2026 - 4Insider transaction report
Aug 12, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 8-KResults of a shareholder vote
Jun 12, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 12, 2026 - 8-KResults of operations and financial condition
May 12, 2026